Login

Paul MampillyPaul Mampilly

Back when Paul Mampilly was growing up in India, nobody talked about the stock market. Yet as a kid, Paul read voraciously about the Great Crash of 1929 and found it fascinating.

When he turned 18, he came to the United States by himself. Since then, he’s had close to 25 years of investment experience, and he’s been through every kind of job in finance.

He’s covered biotech and health care as an analyst and portfolio manager for major international banks such as Deutsche Bank, ING and Bankers Trust. He writes:

I’ve been part of a team managing a $23 billion mutual fund and a $6 billion hedge fund that Barron's named as one of the world's best hedge funds in 2008.

My clients have included European aristocracy, the Templeton Foundation, Swiss private banks, Fortune 500 companies like Sears and giant banks like the Royal Bank of Scotland.

He’s learned investing through experience, and he taught himself molecular biology simply by reading books. In fact, Paul has a personal library of over 1,000 books, and he never stops buying more. “On average, I read over 50 books a year and consume over 100 email news items every single day,” he says.


New Catalysts Making 2 of Our Stocks Strong Buys

If you bought this biotech company when we recommended it in August 2014, you made over 60% in less than six months. That’s an annualized gain of more than 120%. Congratulations and well done!!! We sent you an alert on Monday telling you to SELL your shares. If you haven’t done so already, sell your stock and pocket that sweet 60% profit.

Important: Flash Alert

Yesterday, this stock was down over 10% because a clinical study did not show positive results. This was a small, early stage study for a disease called rheumatoid arthritis. It's a non-event. Clever investors use non-events like this to bang stocks down all the time. I know their tactics from when I managed a $5 billion hedge fund.

Make 1,529% in 17 Months Because of the First Flu Epidemic in a Decade

Fifteen children have died so far from the flu this season. In North Carolina, seven people died from the flu last week. Indiana just reported that the flu killed 31 people the week of Dec. 27… During that H3N2 flu outbreak, this tiny Australian biotech's stock soared from $7.66 to $41.29, a gain of 439%. I believe this tiny Australian biotech's stock is set to do it again now…